Tisagenlecleucel (Kymriah) CAR-T therapy
Customize your policy alerts
Sign up for Baylor Scott & White Health Plan Policy 279 alerts
Get alerted when Policy 279 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and prior authorization for tisagenlecleucel (Kymriah) in members receiving CAR-T therapy. Coverage is considered for specified B-cell precursor acute lymphoblastic leukemia and B-cell lymphoma indications when universal and indication-specific criteria are met.
The policy added criteria requiring the prescriber to be or consult with a board-certified hematologist or oncologist and requiring appropriate candidate assessment for apheresis.
The policy added additional follicular lymphoma criteria.
The policy revised universal CAR-T criteria, including prescriber, dosing and administration, monotherapy, apheresis, prior CAR-T treatment, anti-CD19 treatment, and exclusion requirements.
The policy history states that the REMS program requirement was removed.
The policy was updated on September 24, 2026 to update coding information.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.